PO.TB10.12 · 肿瘤生物学
弥合转化鸿沟:人类PDAC与小鼠模型之间关键的TME差异
Bridging the translational gap: Critical TME differences between human PDAC and mouse models
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:胰腺导管腺癌(PDAC)在致密、异质的肿瘤微环境(TME)中发展,其中胶原和透明质酸(HA)塑造了组织结构、生物力学和治疗应答。尽管小鼠PDAC模型被广泛使用,但其重现人类细胞外基质(ECM)组织结构的能力仍不确定。本研究旨在定量比较人类PDAC与一种常用小鼠模型中的ECM组成和空间拓扑结构。
方法:将来自原发性人类PDAC(n=6)和同基因PDAC小鼠模型(n=3)的组织切片进行H&E染色以及天狼星红(胶原)和阿尔新蓝(HA)双重染色方案。小鼠模型通过在批准的方案下将2838c3细胞皮下植入C57BL/6小鼠而建立,肿瘤在约100 mm³时切除。使用Agilent Lionheart在相同条件下采集高分辨率明场图像。使用CerFlux PEER AI/ML成像和分析平台对63项组织形态测量和空间参数(包括面积分数、边缘至核心定位和纹理)进行定量分析,并在Fiji中交叉验证。使用灰度共生矩阵特征和Moran's I对纹理和空间有序性进行定量。
结果:人类PDAC表现出平衡的ECM组成(胶原=0.16±0.04;HA=0.18±0.04),而小鼠肿瘤表现出HA富集和胶原缺乏(胶原=0.04±0.002;HA=0.26±0.09)。边缘图谱显示人类样本中胶原和HA成比例(边缘比=0.9±0.46),但小鼠肿瘤中外周胶原富集达4倍(边缘比=4.3±1.3)。人类肿瘤表现出更高的熵值(胶原=8.1±0.2;HA=7.9±0.2)和显著的HA自相关(Moran's I=0.58±0.22;0.60±0.42),反映异质性、区域聚集的促结缔组织增生。小鼠肿瘤表现出降低的熵值(约7.8)和较低的Moran's I(0.32±0.05;0.17±0.01),提示有序的、包膜样的ECM组织。主成分分析清晰地区分了物种:PC1(42%)为胶原-HA平衡,人类样本得分为正而小鼠样本为负;PC2(21%)为纹理异质性对边缘定位有序性。
结论:这些发现表明,小鼠PDAC模型未能重现人类PDAC平衡的胶原-HA组成和空间无序的促结缔组织增生,而是形成一个富含HA、胶原缺乏的核心,外包一层有序的胶原包膜,其间质熵值和自相关明显更低。这些发现凸显了小鼠模型(尤其是皮下肿瘤模型)的局限性,并强调了对与人类相关的新方法(NAMs)用于转化治疗研究的需求。
查看英文原文 English abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) develops within a dense, heterogeneous tumor microenvironment (TME) in which collagen and hyaluronic acid (HA) shape tissue architecture, biomechanics, and therapeutic response. Although mouse PDAC models are widely used, their ability to recapitulate human extracellular matrix (ECM) organization remains uncertain. This study aimed to quantitatively compare ECM composition and spatial topology in human PDAC versus a commonly used mouse model.
Methods: Tissue sections from primary human PDAC (n=6) and a syngeneic PDAC mouse model (n=3) were stained with H&E and a dual Picrosirius Red (collagen) and Alcian Blue (HA) protocol. The mouse model was generated by subcutaneous implantation of 2838c3 cells into C57BL/6 mice under approved protocols, with tumors resected at ~100 mm³. High-resolution brightfield images were acquired under identical conditions using Agilent Lionheart. Quantitative analyses across 63 histomorphometric and spatial parameters, including area fractions, edge-to-core localization, and texture, were performed using the CerFlux PEER AI/ML imaging and analytics platform and cross-validated in Fiji. Texture and spatial order were quantified using gray-level co-occurrence matrix features and Moran's I.
Results: Human PDAC exhibited balanced ECM composition (collagen=0.16±0.04; HA=0.18±0.04), whereas mouse tumors showed HA enrichment and collagen depletion (collagen=0.04±0.002; HA=0.26±0.09). Edge mapping revealed proportionate collagen and HA in human samples (edge ratio=0.9±0.46) but 4-fold peripheral collagen enrichment in mouse tumors (edge ratio=4.3±1.3). Human tumors demonstrated higher entropy (collagen=8.1±0.2; HA=7.9±0.2) and substantial HA autocorrelation (Moran's I=0.58±0.22; 0.60±0.42), reflecting heterogeneous, regionally clustered desmoplasia. Mouse tumors displayed reduced entropy (~7.8) and lower Moran's I (0.32±0.05; 0.17±0.01), indicative of ordered, capsule-like ECM organization. Principal component analysis distinctly segregated species: PC1 (42%) collagen-HA balance, with human samples scoring positive and mouse samples negative; PC2 (21%) textural heterogeneity versus edge-localized order.
Conclusions: These findings show that the murine PDAC model fails to reproduce the balanced collagen-HA composition and spatially disordered desmoplasia of human PDAC, instead forming an HA-rich, collagen-depleted core encased in an ordered collagen capsule with markedly lower stromal entropy and autocorrelation. These findings highlight the limitations of mouse models, particularly subcutaneous tumor models, and underscores the need for human-relevant new approach methods (NAMs) for translational therapeutic studies.
利益披露 Disclosure
R. Guenter,
CerFlux Employment.
L. A. Boykin,
CerFlux Employment.
K. K. Budhwani,
CerFlux Patent.
B. K. Budhwani,
CerFlux Patent.
C. L. Crawford,
CerFlux Employment.
J. Rose, None.
K. I. Budhwani,
CerFlux Employment, g., Board of Directors, non-salaried role), Stock, Patent.